Related Experiment Video
Updated: Dec 8, 2025
04:49
Author Spotlight: Investigating the Underlying Mechanisms of Right Ventricular Failure in Pulmonary Hypertension
Published on: June 14, 2024
1.1K
NT-pro-BNP in patients with left ventricular hypertrabeculation/non-compaction.
Katharina Rapatz1, Josef Finsterer1, Astrid Voill-Glaninger1
1Klinik Landstrasse, Vienna, Austria.
ESC Heart Failure
|September 23, 2020
Summary
High levels of N-terminal fragment of the pro brain natriuretic peptide (NT-pro-BNP) indicate a poor prognosis in patients with left ventricular hypertrabeculation/non-compaction (LVHT). These findings suggest NT-pro-BNP can predict adverse outcomes like death or heart transplantation in LVHT patients.
Area of Science:
- Cardiology
- Biomarkers
- Cardiac Imaging
Background:
- Left ventricular hypertrabeculation/non-compaction (LVHT) is a cardiac abnormality with unknown causes, often linked to neuromuscular disorders.
- The prognostic value of N-terminal fragment of the pro brain natriuretic peptide (NT-pro-BNP) in LVHT patients remains largely unestablished.
Purpose of the Study:
- To evaluate the role of NT-pro-BNP levels as prognostic indicators in individuals diagnosed with LVHT.
- To determine the association between NT-pro-BNP levels and clinical/echocardiographic parameters in LVHT.
Main Methods:
- Retrospective analysis of data from 113 LVHT patients, collected since 1996.
- Assessment of NT-pro-BNP levels and correlation with baseline clinical and echocardiographic data.
- Follow-up evaluation for endpoints including death and heart transplantation.
Main Results:
- Elevated NT-pro-BNP levels correlated with heart failure, valvular issues, diabetes, hypertension, angina, affected LVHT segments, and impaired systolic function.
- During a median follow-up of 73 months, 35% of patients experienced an endpoint.
- High NT-pro-BNP levels significantly predicted adverse outcomes (P < 0.001).
Conclusions:
- Elevated NT-pro-BNP levels serve as significant indicators for adverse events, including death and heart transplantation, in LVHT patients.
- NT-pro-BNP is a valuable prognostic biomarker in the management of LVHT.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
398
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
398
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
234
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
234
01:29Heart Failure II: Pathophysiology
506
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
506
01:23Mitral Stenosis II: Clinical features and Diagnostic Tests
117
Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
117
01:22Mitral Valve Prolapse II: Assessment and Management
218
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
218
01:20Mitral Regurgitation I: Introduction
222
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
222